Shares of Envoy Medical, a hearing implant maker, <a href="https://www.marketwatch.com/investing/stock/coch?utm_source=in_materials">rose</a> nearly 9% on Thursday, November 14, buoyed by earnings for the first nine months of the year. While the top line declined over 17% year over year, the company’s loss per share narrowed almost 60%. Earlier, Envoy Medical had <a href="https://www.globenewswire.com/news-release/2024/11/14/2981221/0/en/Envoy-Medical-Reports-Third-Quarter-2024-Results-and-Other-Exciting-Events.html?utm_source=in_materials">announced</a> U.S. regulatory approval to start trials on one of its hearing implants and CPT codes for another. The latter development paves the way for potential insurance coverage for the device.

Hearing implant maker Envoy Medical rises on nine-month earnings

Shares of hearing implant developer Envoy Medical <a href="https://www.nasdaq.com/market-activity/stocks/coch">surged</a> almost 20% on Monday, August 12. Before the market opened, the company <a href="https://finance.yahoo.com/news/envoy-medical-reports-second-quarter-123400733.html">reported</a> its second-quarter 2024 results and announced that, after 18 months of preliminary research on its cochlear implant — which essentially replaces the function of the inner ear — it plans to move forward to a clinical trial.

#: 2